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ABSTRACT
The Brazilian municipality of Rondonópolis, Mato Grosso State, represents an important 
visceral leishmaniasis (VL) endemic area. This study described epidemiological and clinical 
aspects of the occurrence, VL/HIV coinfection and lethality related to VL in Rondonópolis. 
Data from autochthonous cases reported between 2011 and 2016 were obtained from official 
information systems. During this period, 81 autochthonous cases were reported, with decreasing 
incidence through 2016. Contrastingly, the lethality rate was 8.6% overall, but varied widely, 
reaching a peak (20%) in 2016. Almost 10% of patients had VL/HIVcoinfection. The occurrence 
of VL prevailed among men (56.8%), brown-skinned (49.4%), urban residents (92.6%), aged 
0-4 years (33.3%). Housewives or retired (29.6%) were the most affected occupational groups. 
Lower age was the main difference among the total VL cases and those who were coinfected 
or died. Clinically, fever, weakness and splenomegaly were more frequent among all VL cases 
and VL/HIV coinfected individuals. Bacterial infections (p=0.001) and bleeding (p<0.001) 
were associated with death due to VL. Pentavalent antimonial and liposomal amphotericin B 
were the first choices for treatment among all VL cases (71.6%) and those who died (71.4%), 
respectively. VL/HIV patients were equally treated with both drugs. These findings may support 
control measures and demonstrate the need for further investigations.
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INTRODUCTION
Visceral leishmaniasis (VL), or kala-azar, is a vector-borne zoonotic disease that 
represents a challenge for Brazilian public health, mainly due to its recent expansion 
to medium and large urban areas1, in addition to high rates of associated mortality2. 
Brazil is among the six countries that comprise 90% of VL cases worldwide3, where 
approximately 3,500 new cases are reported annually, with an average lethality of 
8.1%2,4. 
Death outcomes in VL are often related to delayed diagnosis5, drug toxicity6, and 
inadequate management of patients with signs of unfavorable disease evolution7,8. 
In this regard, age <5 and >40-50 years, jaundice, thrombocytopenia, bleeding, 
diarrhea, severe neutropenia, dyspnea, and bacterial infections were recently 
revised as stronger prognostic factors for death due to VL7. In addition, human 
immunodeficiency virus (HIV) co-infections deserve attention as a factor commonly 
associated with VL lethality9. In Brazil, the number of individuals with VL/HIV 
coinfections has been increasing and this population presents three times higher 
lethality than patients without VL/HIV coinfections10. 
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Therefore, it is important to evaluate the occurrence of 
VL in endemic areas, as well as the characteristics among 
VL/HIV coinfected patients and those who evolved to 
death due to VL. These contributions are crucial for the 
development, optimization and conduction of strategies 
to control the disease and achieve better management of 
patients9-11.
In the past decade, the Brazilian municipality of 
Rondonópolis has emerged as an important VL endemic 
area. According to Werneck12, from 2001 to 2012, 
Rondonópolis was among the ten cities responsible 
for 15.0% of VL cases reported in Brazil. Despite this 
great importance, the area lacks studies regarding the 
disease occurrence. The only report described the spatial 
distributions of human cases, reservoirs and vectors13. 
Thus, the present study aimed to describe epidemiological 
and clinical aspects of the occurrence, VL/HIV coinfection 
and lethality of VL in the municipality of Rondonópolis 
between 2011 and 2016.
MATERIALS AND METHODS
Design and study area
This is a retrospective sectional and descriptive 
study carried out in Rondonópolis (16°28’15”S and 
54°38’08”W), an agricultural and industrial reference 
center located in the South of Mato Grosso State in 
Central-Western Brazil. Although the State includes 
regions of Amazonia and Pantanal, Rondonópolis is 
located in the Cerrado biome. The municipality has an 
estimated population of 222,316 inhabitants and a total 
area of 4,159.12 km2, of which 129.2 km2 are located in the 
urban area14. The actions of the National VL Surveillance 
and Control Program are currently carried out by public 
health authorities and are focused on humans, reservoirs 
and vectors15.
Data collection
Data were obtained by the individual analysis of VL 
notification/investigation forms and death certificates 
available from the Brazilian Notifiable Diseases Information 
and Mortality Information Systems, respectively, which are 
coordinated by the Epidemiological Surveillance Sector 
of the Municipal Health Department of Rondonópolis. 
All autochthonous cases reported and confirmed in the 
municipality from resident individuals, between 2011 and 
2016, were included. Relapses or cases reported in duplicate 
were excluded. In order to estimate the annual incidence 
of VL in Rondonópolis, the annual population estimates 
from the Brazilian Institute of Geography and Statistics 
were used14.
Data analysis
Data were tabulated and the patients were divided into 
three groups for the characterization of epidemiological and 
clinical features: total VL cases (all autochthonous VL cases 
reported in Rondonópolis), VL/HIV cases (all autochthonous 
cases of VL/HIVcoinfection) and deaths due to VL (all deaths 
related to VL). It is important to note that the last two groups 
are contained in the first. Descriptive statistics were used for 
the analysis in MicrosoftTM Office Excel 2010 (Microsoft 
Corp., Santa Rosa, CA, USA) and Epi InfoTM version 
7.2 (CDC, Atlanta, GA, USA). Fisher’s exact tests were 
performed to verify associations between groups and clinical 
manifestations and to compare lethality among patients with 
VL/HIV coinfections and those without. Both analyses were 
conducted using STATA/SE 11.0 (StataCorp LP, College 
Station, TX, USA). Differences with a p-value < 0.05 were 
considered statistically significant.
RESULTS
During the evaluated period, 117 VL cases were reported 
in Rondonópolis, of which 81 (69.2%) were new and 
autochthonous. The highest incidence of VL was observed 
in 2011 (12.1/100,000 inhabitants), followed by 2012 
(7.9/100,000 inhabitants) and a sharp decline until 2016 
(4.6/100,000 inhabitants). In contrast, the overall lethality 
rate was 8.6%, but varied widely over the years, reaching 
a peak of 20.0% in 2016 (Figure 1).
Table 1 summarizes the epidemiological aspects for all 
autochthonous VL cases reported in Rondonópolis (n = 81), 
Figure 1 – Number of cases, incidence and lethality rate due 
to visceral leishmaniasis in the municipality of Rondonópolis, 
Mato Grosso State, Brazil, between 2011 and 2016. To calculate 
the incidence, the following population estimates provided 
by the Brazilian Institute of Geography and Statistics were 
used: 2011/198,949 inhabitants; 2012/202,309 inhabitants; 
2013/208,019 inhabitants; 2014/211,718 inhabitants; 
2015/215,320; 2016/218,899 inhabitants
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Table 1 – Epidemiological characteristics related to the total cases of visceral leishmaniasis (total VL cases), VL/HIV coinfection 
(VL/HIV cases) and lethality due to VL (deaths due to VL) reported in the municipality of Rondonópolis, Mato Grosso State, Brazil, 
between 2011 and 2016
Variable
Group




Deaths due to VL 
(N = 7)
N % N % N %
Sex
Male 46 56.8 6 75.0 6 85.7
Female 35 43.2 2 25.0 1 14.3
Ethnic group
Brown 40 49.4 4 50.0 6 85.7
White 29 35.8 2 25.0 - -
Black 10 12.3 2 25.0 1 14.3
Ignored / blank 2 2.5 - - - -
Residential area
Urban 80 98.8 8 100.0 7 100.0
Rural 1 1.2 - - - -
Age group (years)
0 – 4 27 33.3 - - - -
5 – 9 4 4.9 - - - -
10 – 19 3 3.7 - - - -
20 – 29 8 9.9 1 12.5 - -
30 – 39 16 19.8 3 37.5 2 28.6
40 – 49 11 13.6 2 25.0 1 14.3
50 – 59 5 6.2 2 25.0 1 14.3
≥ 60 7 8.6 - - 3 42.8
Educational level ±
Illiterate or primary education (incomplete) 10 18.5 3 37.5 2 28.6
Primary education 17 31.5 4 50.0 2 28.6
Elementary education 7 13.0 - - 1 14.2
Secondary education or higher education 11 20.4 - - - -
Ignored / blank 9 16.6 1 12.5 2 28.6
Occupation ±
Housewife or retired 16 29.6 4 50.0 3 42.8
Unemployed 7 13.0 3 37.5 3 42.8
Student 7 13.0 - - - -
Building construction job 5 9.3 - - - -
Self employed 4 7.4 - - - -
Others 14 25.9 1 12.5 - -
Ignored / blank 1 1.8 - - 1 14.4
HIV co-infection
Yes 8 9.9 8 100.0 2 28.6
No 66 81.5 - - 5 71.4
Ignored / blank 7 8.6 - - - -
± Infants or young children aged 0 – 4 years (N=27) were not included in these variables.
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VL/HIV cases (n = 8) and deaths due to VL (n = 7). The 
occurrence of disease prevailed among men (56.8%), 
brown-skinned individuals (49.4%) from the urban area 
of the municipality (92.6%). Although the median patient 
age was 31.1 years (range 0.3 to 81.3 years), children 0 
to 4 years of age comprised most of the cases (33.3%), 
followed by adults 30 to 39 years of age (19.8%). Excluding 
children, VL was more frequent among individuals with 
low educational level. In addition, housewives or retired 
(29.6%), unemployed (13.0%) and students (13.0%) were 
the most affected occupational groups.
VL/HIV coinfection was observed in 9.9% of the 
autochthonous VL cases, although in 8.6% of the forms, 
this field was ignored or not filled. These subjects, as well 
as those who died due to VL, shared epidemiological 
similarities, mainly because they were predominantly male 
(75.0% and 83.3%, respectively), brown-skinned (50.0% 
and 83.3%), all urban residents, with low educational level, 
housewives or retired (50.0% and 37.5%), and unemployed 
(42.8%). The median patient age in the coinfected and 
mortality groups were higher, at 39.8 and 55.9 years, 
respectively, predominantly among those in the range of 
30-39 (37.5%) and > 60 (50.0%) years of age, respectively. 
Excluding patients with unknown HIV infection status, no 
significant difference was found in lethality related to VL 
between individuals who were VL/HIV coinfected (25%, 
2/8) and non-coinfected (7.6%, 5/66) (p = 0.163) (data not 
shown).
Fever (95.1%), weakness (82.7%) and splenomegaly 
(79.0%) were the most common clinical manifestations 
among VL cases, although signs of severe disease were 
frequently observed, including jaundice (33.3%) and edema 
(18.5%). In VL/HIV coinfected patients, there was a high 
frequency of bacterial infections (37.5%) and bleeding 
(25.0%), in addition to the classical manifestations. As 
expected, severe and diversified manifestations were 
observed among those patients who evolved to death due to 
VL. In this sense, bacterial infections (85.7%) (p = 0.001) 
and bleeding (71.4%) (p < 0.001) were significantly 
associated with death outcome (Table 2).
Table 2 – Frequency of clinical manifestations among the total cases of visceral leishmaniasis (total VL cases), VL/HIV coinfection 
(VL/HIV cases) and lethality due to VL (deaths due to VL) reported in the municipality of Rondonópolis, Mato Grosso State, Brazil, 
between 2011 and 2016 
Clinical manifestation
Group




Deaths by VL 
(N = 7)
N % CI 95% N % CI 95% p-value± N % CI 95% p-valueϕ
Fever 77 95.1 87.6-98.4 8 100.0 67.6-100.0 1.000 7 100.0 64.6-100.0 1.000
Weakness 67 82.7 73.1-89.4 7 87.5 52.9-97.8 1.000 6 85.7 48.7-97.4 1.000
Splenomegaly 64 79.0 68.9-86.5 7 87.5 52.9-97.8 0.683 7 100.0 64.6-100.0 0.335
Hepatomegaly 63 77.8 67.6-85.5 8 100.0 67.6-100.0 0.587 7 100.0 64.6-100.0 0.338
Weigh loss 63 77.8 67.6-85.5 7 87.5 52.9-97.8 0.677 6 85.7 48.7-97.4 1.000
Pallor 62 75.3 66.3-84.4 6 75.0 40.9-92.9 0.985 6 85.7 48.7-97.4 0.675
Jaundice 26 32.1 22.9-42.9 2 25.0 7.2-59.1 0.719 3 42.9 15.8-75.0 0.675
Cough and/or diarrhea 25 30.9 21.9-41.6 2 25.0 7.2-59.1 1.000 2 28.6 8.2-64.1 1.000
Bacterial infections 22 27.2 18.7-37.7 3 37.5 13.7-69.4 0.676 6 85.7 48.7-97.4 0.001*
Edema 14 17.3 10.6-27.0 1 12.5 2.2-47.1 1.000 1 14.3 2.6-51.3 0.597
Blood dyscrasias 8 9.9 5.1-18.3 - - - - 1 14.3 2.6-51.3 0.981
Bleeding 7 8.6 4.3-16.8 1 12.5 2.2-47.1 0.981 5 71.4 35.9-91.8 <0.001*
Headache 2 2.5 0.7-8.6 - - - - - - - -
Abdominal distension 2 2.5 0.7-8.6 - - - - 1 14.3 2.6-51.3 -
Arrhythmia 1 1.2 0.2-6.7 - - - - - - - -
Itchy face 1 1.2 0.2-6.7 - - - - - - - -
Kidney and liver failure 1 1.2 0.2-6.7 - - - - 1 14.3 2.6-51.3 -
Pneumonia 1 1.2 0.2-6.7 - - - - 1 14.3 2.6-51.3 -
±Comparison of proportions of clinical manifestations between VL/HIV co-infected and non-co-infected VL patients. ϕComparison of 
proportions of clinical manifestations between VL patients who evolve to death and VL patients who do not. *Significant at Fisher 
exact test.
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VL treatment was initially performed mainly with 
pentavalent antimonial in all cases (71.6%), with drug 
failure and cure reported in 7.4% and 71.6% of the patients, 
respectively. Liposomal amphotericin B was used to treat 
the majority (71.4%) of those who died due to VL, with 
only one (14.3%) drug failure report in this group. For 
VL/HIV cases, the use frequency of the two drugs was 
the same (50.0%). Drug failure and cure were reported in 
12.5% and 62.5% of these patients, respectively (Table 3). 
DISCUSSION
The current expansion of VL in Brazilian territories 
represents a clinical and epidemiological concern for public 
health authorities and health professionals, especially due 
to the complexity associated with its control and clinical 
management1,4,8. The State of Mato Grosso is historically 
endemic for VL16, with the municipality of Rondonópolis 
containing almost half of the human cases reported there 
in recent years, being an area of intense VL transmission 
with regional and national relevance12,13.
In this context, the geographical localization of 
the municipality is a topic that deserves attention. 
Rondonópolis is nearby and easily connected by transport 
routes to the municipality of Campo Grande, State of Mato 
Grosso do Sul, which previously emerged as a highly 
endemic area in 200117. Going North, Rondonópolis 
also represents the main path of entrance to the West 
Amazonian Basin, where some States with no reporting 
of autochthonous human VL cases, such as Rondônia and 
Amazonas are located18. Considering the possibility of 
vectors and reservoirs dispersion, as well as the intense 
demographic flow between these areas, Rondonópolis 
could contribute to the installation of human VL in these 
settings18-20, as recently proposed by Sevá et al.21 in the 
State of São Paulo, Brazil.
Despite the observed decline in VL over the evaluated 
years, the incidence of the disease in Rondonópolis was 
considerable higher than the Brazilian average, which 
ranged from 1.6 to 2.0 new cases/100,000 inhabitants per 
year between 2011 and 201522. Consequently, the absolute 
number of reported autochthonous cases also decreased with 
maintenance of high endemicity levels. This stabilization 
has also been noted in official data from Brazil between 
2011 and 201523, and may be related to control measures 
along with lasting immunity developed in the affected 
populations, which probably generates herd immunity1. 
However, considering the reemergence potential of VL, 
these observations should be interpreted with caution, 
since changes in the natural environment associated with 
favorable epidemiological conditions may lead to large 
outbreaks and epidemics24.
Table 3 – Treatment aspects and outcomes related to the total cases of visceral leishmaniasis (total VL cases), VL/HIV coinfection 
(VL/HIV cases) and lethality due to VL (deaths due to VL) reported in the municipality of Rondonópolis, Mato Grosso State, Brazil, 
between 2011 and 2016 
Variable
Group




Deaths by VL 
(N = 7)
N % N % N %
Initial treatment
Pentavalent antimonial 58 71.6 4 50.0 2 28.6
Liposomal amphotericin B 17 21.0 4 50.0 5 71.4
Amphotericin B deoxycholate 3 3.7 - - - -
Ignored / blank 3 3.7 - - - -
Drug failure
Yes 6 7.4 1 12.5 1 14.3
No 71 87.7 6 75.0 6 85.7
Ignored / blank 4 4.9 1 12.5 - -
Outcome±
Cure 73ϕ 90.2 6 75.0 - -
Death by VL 7 8.6 2 25.0 7 100.0
Death by others causes 1 1.2 - - - -
± Information were checked at the Brazilian Mortality Information System. ϕThe HIV infection status of seven of these patients was 
unknown.
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On the other hand, lethality has been increasing in 
Rondonópolis, similar to observations in the State of 
Alagoas25 and nationwide26. In addition, the overall lethality 
rate in the present study (8.6%) was considerable and similar 
to the national average (8.1%)2. Case fatality related to VL is 
usually the consequence of incorrect and/or late diagnosis5, 
drug toxicity6, delay in the management of patients who 
are at higher risk of progressing to death7,8, presence of 
comorbidities such as malnutrition, cardiovascular diseases 
and immunosuppression, which may evolve to progressive 
and fatal weakness2,7,27.
Indeed, in Rondonópolis, a high occurrence of patients 
with VL/HIV coinfection (9.9%) was found, a higher 
percentage than the one recently reported in Brazil, where 
the overall percentage of coinfection was approximately 
8.5% in 201328. This is probably related to the increasing 
AIDS detection rate that has recently been observed in 
the municipality29, and in other medium and small cities 
located in North and Central-Western Brazil30,31. Thus, this 
pattern of occurrence of the HIV infection along with the 
urbanization of VL provided the geographical juxtaposition 
of both diseases4,30. In Rondonópolis, this co-occurrence 
may have been enhanced because this city is a hub of 
regional entrenchment with accelerated demographic and 
socioeconomic flow32.
Although the observed case fatality among VL/HIV 
coinfected patients who were investigated in the present 
study was statistically similar to the non-coinfected, the 
absolute rate was higher, as similarly reported for the whole 
country10. The relationship between VL/HIV coinfection 
and VL lethality is not well elucidated because it is not 
known whether the severity is due to HIV infection or 
consequent opportunistic infections33. Taken together, 
these findings reinforce the idea that lethality related to 
VL is a current major concern and underscore the need 
for improving the diagnosis and management of patients, 
including HIV infection screening10,33.
Except for age groups, the epidemiological profile of 
VL in Rondonópolis did not differ substantially among 
the evaluated groups. Children aged 0 to 4 years were the 
most affected group among VL cases. This pattern was also 
described by several studies in Brazil11,34,35 and abroad36,37 
and may be related to the fact that, when compared to 
adults, children have more contact with animal reservoirs 
and vectors, they have immature immunity and frequent 
nutritional deficits38. 
Surprisingly, there was no record of VL case fatality 
among children, as detected in other studies33,39. This 
outcome was observed only in adults, especially among 
the elderly, where immunological decline occurs and 
comorbidities are more frequent33,39. Indeed, VL/HIV 
coinfection was observed exclusively in adults, which is 
expected due to the decreasing in HIV incidence among 
children, mainly due to improvements in the prevention of 
vertical transmission40. 
In relation to gender, men were the most affected. 
Although women are equally susceptible to the disease 
and fatality, this slight predominance may be related to 
behavioral differences due to the presence of men in areas at 
higher risk of phlebotomine sand fly bites35,41. Furthermore, 
Guerra-Silveira and Abad-Franch42 demonstrated that the 
risk of VL is significantly male-biased during the first 
year of life, puberty, reproductive age and in elderly, 
corroborating with the high occurrence of the disease 
in these age groups herein detected. A lower proportion 
of VL/HIV coinfected women was also described10 and 
corroborates the sex ratio of HIV/AIDS patients in the 
municipality of Rondonópolis, which was 1.4 cases in men 
for one case in women, in 201429.
The predominance of VL among urban residents 
is consistent with the expansion of the disease to large 
cities observed in Brazil since the 1980s, mainly due to 
demographic, environmental, and sanitary factors2,19 . In 
Rondonópolis, this process began in the 2000s and may 
have been influenced by the disorderly growth of the city, 
migration waves, accelerated population increase, expansion 
of agriculture, industrialization and the emergence of spaces 
with marked intra-urban differences43, as detected in other 
regions of the country19,34,35,38.
The higher occurrence and lethality of VL among 
individuals with low educational level has evidenced 
the socioeconomic vulnerability usually associated with 
VL44, showing that a lack of schooling can influence 
health knowledge and practices focused on prevention45. 
In this context, Borges et al.46 demonstrated that increased 
schooling is a protective factor that reduced the risk of VL 
by 0.64-fold in the city of Belo Horizonte, Brazil.
Individuals who supposedly remained longer at home 
(minors and infants, housewives, retired, unemployed and 
students) were more affected by the disease. These findings 
suggest the importance of the intra and peri-domiciliary 
environments in the VL transmission cycle, where reservoirs 
and vectors are usually found45,47.
The clinical manifestations of VL observed in the 
present study are concordant with those reported by other 
studies41,48. Fever, weakness, hepatomegaly, weight loss and 
splenomegaly were frequent among VL cases and comprise 
the classic clinical features of the disease, generally 
found at the patients admission49. Curiously, anemia and 
pancytopenia (blood dyscrasias) were not detected at high 
frequencies, although pallor was often reported. These 
signals are commonly associated with symptomatic VL50,51 
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and are due to blood loss, erythropoiesis dysfunction, and/or 
up-regulated destruction of erythrocytes, among other 
factors41,52.
On the contrary, jaundice, bacterial infections, edema 
and bleeding were often reported, especially among patients 
who died due to VL. These clinical scenarios are related 
to VL progression, poor prognosis7,48,53 and may indicate a 
late diagnosis; thus, it is essential that health professionals 
are aware of these signs, which are easily detected in early 
health services such as emergency care and basic health 
units35,48.
Among VL/HIV coinfected individuals, the clinical 
presentations of VL were similar to those found in VL 
cases. According to Lindoso et al.54, this is usually verified 
in clinical practice, so that unusual manifestations tend to 
occur among patients with very low CD4+ T-cell counts55. 
Unfortunately, the data in the present study did not allow 
us to check this relationship by assessing the level of these 
cells. 
Due to its zoonotic nature in Brazil, VL treatment has 
a limited impact on disease transmission, but is essential 
for the patient15. However, the available arsenal remains 
scarce, in addition to presenting problems related to 
acceptance, efficacy, side effects and high cost6,56. Similar to 
observations by Petrela et al.57, pentavalent antimonial was 
the first-line drug for the treatment of most autochthonous 
cases in Rondonópolis, with low drug failure. Indeed, 
meglumine antimoniate at 20 mg/kg/day for 20-40 days has 
been the standard treatment for VL in Brazil, with no report 
of drug resistance and high cure rates15. However, due to the 
risk of adverse effects such as cardiotoxicity, pancreatitis 
and nephrotoxicity, patients should be monitored or 
hospitalized during therapy58.
In this sense, liposomal amphotericin B is recommended 
as the first choice for the treatment of VL patients with 
nephropathies and heart diseases in Brazil, as well as 
individuals who are over 50 years of age, immunosuppressed 
and with signs of severe VL disease59. The lipid formulation 
assures the delivery of large drug doses in less time with low 
toxicity60. Taken together, the national recommendations 
support our observation of the increased use of liposomal 
amphotericin B among VL/HIV coinfected patients and in 
those who died in the municipality of Rondonópolis.
The main limitation of the present study was the 
use of secondary data, which is susceptible to lack of 
information. Nevertheless, our investigation presents an 
important epidemiological and clinical overview of the 
occurrence, VL/HIV coinfection and lethality due to VL 
in the municipality of Rondonópolis, which represents an 
important endemic Brazilian area with intense transmission. 
Thus, these data may be useful to help the planning of 
integrated public health policies focused on VL prevention, 
early detection and patients’ management. Moreover, the 
results of this study also demonstrated the need for future 
and more robust investigations involving humans, reservoirs 
and vectors in the area. 
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